Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01124045 · ClinicalTrials.gov registry record · Phase 3

Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery

A Phase 3 study, sponsored by Alcon Research.

Completed
Registry status
Phase 3
Development phase
80
Enrollment target

NCT01124045 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 80 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01124045, a Phase 3 study, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 3
Development phase
80 participants
Enrollment target

Study Summary

The primary objective of this study was to compare the safety and efficacy of Durezol™ compared to Pred Forte™ for the treatment of inflammation following cataract surgery in a pediatric population 0 to 3 years of age.

Interventions

  • DRUG Difluprednate ophthalmic emulsion, 0.05%
  • DRUG Prednisolone acetate ophthalmic suspension, 1.0%

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2010-08
Est. Completion 2012-04
Phase Phase 3

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT01124045

The ClinicalTrials.gov registry entry for NCT01124045 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Difluprednate ophthalmic emulsion, 0.05% is the first listed.

NCT01124045 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01124045 about?

NCT01124045 is a clinical study titled "Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery". The primary objective of this study was to compare the safety and efficacy of Durezol™ compared to Pred Forte™ for the treatment of inflammation following cataract surgery in a pediatric population 0 to 3 years of age.

What is the current status of trial NCT01124045?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2010-08. Estimated completion is 2012-04.

What interventions are being tested in trial NCT01124045?

The interventions under investigation include: Difluprednate ophthalmic emulsion, 0.05% (DRUG), Prednisolone acetate ophthalmic suspension, 1.0% (DRUG).

Who is sponsoring clinical trial NCT01124045?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.